These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 35716849)
1. Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes. Horsley PJ; Koo CM; Eade T; Hsiao E; Emmett L; Brown C; Kneebone A; Hruby G Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):106-117. PubMed ID: 35716849 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific membrane antigen positron emission tomography detected local failure after post-prostatectomy radiation therapy: Low rates of out-of-field recurrence validates current Australian prostate bed contouring guidelines. Shakespeare TP; Yap SZL; Hsieh M; Tahir ARM; Armstrong S J Med Imaging Radiat Oncol; 2023 Sep; 67(6):662-667. PubMed ID: 37401187 [TBL] [Abstract][Full Text] [Related]
3. Sonni I; Dal Pra A; O'Connell DP; Ells Z; Benz M; Nguyen K; Yoon SM; Deng J; Smith C; Grogan T; Nickols NG; Cao M; Kishan AU; Calais J J Nucl Med; 2023 Jun; 64(6):902-909. PubMed ID: 36759200 [TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Based Clinical Target Volume Delineation Guideline for Postprostatectomy Salvage Radiation Therapy: The PERYTON Guideline. Staal FHE; Janssen J; Oprea-Lager DE; Engelen AM; van Limbergen EJ; Smeenk RJ; de Jong MAA; Budiharto TCG; Jacobs I; Haverkort DMAD; Brouwer CL; Ng Wei Siang K; Langendijk JA; Verzijlbergen JF; de Jong IJ; Noordzij W; Aluwini S Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):688-696. PubMed ID: 37729971 [TBL] [Abstract][Full Text] [Related]
5. Re-defining Tissot S; Wynn J; Tran V; Farag M; Wong LM; Ng M BJU Int; 2023 Oct; 132(4):411-419. PubMed ID: 37216190 [TBL] [Abstract][Full Text] [Related]
6. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen ( Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951 [TBL] [Abstract][Full Text] [Related]
7. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy. Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332 [TBL] [Abstract][Full Text] [Related]
8. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282 [TBL] [Abstract][Full Text] [Related]
9. Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013 [TBL] [Abstract][Full Text] [Related]
10. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
11. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398 [TBL] [Abstract][Full Text] [Related]
12. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups. Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
14. Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840 [TBL] [Abstract][Full Text] [Related]
15. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995 [TBL] [Abstract][Full Text] [Related]
16. Gallium-68-prostate-specific membrane antigen ( van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [TBL] [Abstract][Full Text] [Related]
17. How accurate is Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066 [TBL] [Abstract][Full Text] [Related]